Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deuterated oxytocin (specifically d5-oxytocin) is a stable isotope-labeled analogue of the nonapeptide hormone oxytocin. It is chemically identical to endogenous and synthetic unlabeled oxytocin, except for the substitution of five hydrogen atoms with deuterium. This modification does not significantly alter the biological activity of the molecule, allowing it to function as a potent agonist of the oxytocin receptor (OXTR). Upon binding, it triggers G-protein coupled signaling pathways that increase intracellular calcium levels, leading to the contraction of uterine smooth muscle (myometrium) and the mammary gland's myoepithelial cells. In clinical research settings, such as pharmacokinetic studies during cesarean deliveries, the deuterated label serves as a molecular tracer. This allows for the precise quantification of the exogenous dose's concentration in plasma using mass spectrometry, effectively distinguishing it from endogenous oxytocin levels and assisting in the optimization of dosing regimens to prevent postpartum hemorrhage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deuterated oxytocin.